Literature DB >> 8935805

5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats.

R A Padich1, T C McCloskey, J H Kehne.   

Abstract

Increasing evidence suggests an important role of 5-HT, and 5-HT2A receptors in particular, in the etiology and treatment of schizophrenia. The prepulse inhibition paradigm is used as a model for sensorimotor gating processes that are disrupted in schizophrenia. The present study used the selective serotonin2A (5-HT2A) antagonist and putative antipsychotic agent MDL 100,907 to evaluate the contribution of 5-HT2A receptors to the disruptions of prepulse inhibition produced by several 5-HT agonists. The D2 antagonist haloperidol was used to evaluate a possible interaction with dopamine neurons. Sound or light prepulses were used to measure the generality of these drug effects on cross-modal prepulse inhibition. In the first study, MDL 100,907 antagonized the disruptions of auditory prepulse inhibition produced by the 5-HT releasing agents fenfluramine and 3,4-methylenedioxymethamphetamine (MDMA). These effects on prepulse inhibition were modality-specific in that MDL 100,907 did not reverse the effects of the 5-HT releasers on visual prepulse inhibition. Haloperidol did not alter the disruptive effects of MDMA or fenfluramine on either auditory or visual prepulse inhibition. In the second study, the direct acting 5-HT2A/2C receptor agonist/hallucinogen (+)1-4-iodo-2,5-dimethoxyphenyl-2-aminopropane (DOI) consistently disrupted auditory prepulse inhibition, and this effect was blocked by MDL 100,907 but not by haloperidol. A dose-response analysis demonstrated that MDL 100,907 potently antagonized DOI disrupted auditory prepulse inhibition, with an ED50 of 0.04 mg/kg, IP. DOI did not consistently disrupt visual prepulse inhibition. In summary, these data indicate that, at least under the conditions of the present studies, the disruptions of auditory prepulse inhibition produced by fenfluramine, MDMA, and DOI result from stimulation of 5-HT2A receptors. Furthermore, these disruptions do not involve direct or indirect stimulation of D2 receptors. The identity of the 5-HT receptor(s) underlying the disruptive effects of fenfluramine or MDMA on visual prepulse inhibition has not yet been identified. MDL 100,907 may be generally useful in CNS disorders in which excessive 5-HT2A receptor tone disrupts sensory gating processes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935805     DOI: 10.1007/bf02245610

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine.

Authors:  N R Swerdlow; R S Mansbach; M A Geyer; L Pulvirenti; G F Koob; D L Braff
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI).

Authors:  R A Glennon
Journal:  Life Sci       Date:  1986-09-01       Impact factor: 5.037

3.  Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.

Authors:  M G Palfreyman; C J Schmidt; S M Sorensen; M W Dudley; J H Kehne; P Moser; M W Gittos; A A Carr
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity.

Authors:  C J Schmidt; J H Kehne; A A Carr; G M Fadayel; T M Humphreys; H J Kettler; T C McCloskey; R A Padich; V L Taylor; S M Sorensen
Journal:  Int Clin Psychopharmacol       Date:  1993-11       Impact factor: 1.659

5.  Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input.

Authors:  H S Hoffman; J R Ison
Journal:  Psychol Rev       Date:  1980-03       Impact factor: 8.934

6.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine.

Authors:  U V Berger; X F Gu; E C Azmitia
Journal:  Eur J Pharmacol       Date:  1992-05-14       Impact factor: 4.432

Review 7.  Molecular biology of serotonin (5-HT) receptors.

Authors:  S J Peroutka
Journal:  Synapse       Date:  1994-11       Impact factor: 2.562

8.  5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex.

Authors:  G C Rigdon; J K Weatherspoon
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

9.  Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat.

Authors:  R S Mansbach; D L Braff; M A Geyer
Journal:  Eur J Pharmacol       Date:  1989-08-11       Impact factor: 4.432

10.  Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.

Authors:  C J Schmidt; V L Taylor
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

View more
  21 in total

1.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Authors:  J H Kehne; R A Padich; T C McCloskey; V L Taylor; C J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.

Authors:  Ignasi Oliveras; Ana Sánchez-González; Daniel Sampedro-Viana; Maria Antonietta Piludu; Cristóbal Río-Alamos; Osvaldo Giorgi; Maria G Corda; Susana Aznar; Javier González-Maeso; Cristina Gerbolés; Gloria Blázquez; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel
Journal:  Psychopharmacology (Berl)       Date:  2017-02-02       Impact factor: 4.530

4.  Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT(1A), but not 5-HT₂ receptor activation.

Authors:  Roberto Stancampiano; Roberto Frau; Valentina Bini; Maria Collu; Manolo Carta; Fabio Fadda; Marco Bortolato
Journal:  Eur Neuropsychopharmacol       Date:  2012-11-06       Impact factor: 4.600

5.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

Review 6.  Effect of Hallucinogens on Unconditioned Behavior.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2018

7.  The effect of corticotropin-releasing factor on prepulse inhibition is independent of serotonin in Brown Norway and Wistar-Kyoto rats.

Authors:  Jane E Sutherland; Michelle E Page; Lisa H Conti
Journal:  Pharmacol Biochem Behav       Date:  2008-01-16       Impact factor: 3.533

Review 8.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

Review 9.  Pre-attentive processing and schizophrenia: animal studies.

Authors:  Bart A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  2003-12-04       Impact factor: 4.530

10.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors:  Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Ashley N Martin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.